Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane F Apperley

Showing results (71-80 of 195) with videos related to

Pageof 20
Sort By:
Blood|March 16, 2002
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemiaJyoti Wadhwa, Richard M Szydlo, Jane F Apperley, et al.
British Journal of Haematology|January 8, 2022
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?Katherine M Dominy, Simone Claudiani, Matthew O'Hare, et al.
Haematologica|May 13, 2017
E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapySimone Claudiani, Jane F Apperley, Robert Peter Gale, et al.
Blood|April 12, 2003
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexEvangelos Terpos, Richard Szydlo, Jane F Apperley, et al.
Blood|September 21, 2007
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutationHugues de Lavallade, Jamshid S Khorashad, Howard P Davis, et al.
European Journal of Haematology|September 30, 2005
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myelomaEvangelos Terpos, Katayoun Rezvani, Supratik Basu, et al.
European Journal of Haematology|January 14, 2017
BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantationOscar M Pello, Andrew J Innes, Anne Bradshaw, et al.
Bone Marrow Transplantation|April 4, 2023
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemiaFiona Fernando, Andrew J Innes, Simone Claudiani, et al.
British Journal of Haematology|January 21, 2010
Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasmsClaire Hidalgo-Curtis, Jane F Apperley, Allistair Stark, et al.
Leukemia|February 29, 2024
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistanceSimone Claudiani, Farhan Chughtai, Afzal Khan, et al.
Pageof 20

Showing results (71-80 of 195) with videos related to

Sort By:
Pageof 20
Blood|March 16, 2002
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemiaJyoti Wadhwa, Richard M Szydlo, Jane F Apperley, et al.
British Journal of Haematology|January 8, 2022
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?Katherine M Dominy, Simone Claudiani, Matthew O'Hare, et al.
Haematologica|May 13, 2017
E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapySimone Claudiani, Jane F Apperley, Robert Peter Gale, et al.
Blood|April 12, 2003
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexEvangelos Terpos, Richard Szydlo, Jane F Apperley, et al.
Blood|September 21, 2007
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutationHugues de Lavallade, Jamshid S Khorashad, Howard P Davis, et al.
European Journal of Haematology|September 30, 2005
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myelomaEvangelos Terpos, Katayoun Rezvani, Supratik Basu, et al.
European Journal of Haematology|January 14, 2017
BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantationOscar M Pello, Andrew J Innes, Anne Bradshaw, et al.
Bone Marrow Transplantation|April 4, 2023
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemiaFiona Fernando, Andrew J Innes, Simone Claudiani, et al.
British Journal of Haematology|January 21, 2010
Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasmsClaire Hidalgo-Curtis, Jane F Apperley, Allistair Stark, et al.
Leukemia|February 29, 2024
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistanceSimone Claudiani, Farhan Chughtai, Afzal Khan, et al.
Pageof 20